Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.

[1]  M. Zillikens,et al.  Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer , 2021, Journal of bone oncology.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  R. Eastell,et al.  Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. , 2020, The Journal of clinical endocrinology and metabolism.

[4]  G. Hortobagyi,et al.  Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307) , 2020, Supportive Care in Cancer.

[5]  T. Kuno,et al.  Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis , 2020, Breast Cancer Research and Treatment.

[6]  A. Díez-Pérez,et al.  Increased Fracture Risk in Women Treated With Aromatase Inhibitors Versus Tamoxifen: Beneficial Effect of Bisphosphonates , 2020, Journal of Bone and Mineral Research.

[7]  M. Mei,et al.  Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials. , 2019, Current problems in cancer.

[8]  C. Shapiro,et al.  Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  E. Lespessailles,et al.  French Recommendations on Strategies for Preventing and Treating Osteoporosis Induced by Adjuvant Breast Cancer Therapies. , 2019, Joint, bone, spine : revue du rhumatisme.

[10]  J. Griggs,et al.  Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Livi,et al.  Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial. , 2019, European journal of cancer.

[12]  I. Reid,et al.  Fracture Prevention with Zoledronate in Older Women with Osteopenia , 2018, The New England journal of medicine.

[13]  Jacques P. Brown,et al.  Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo‐Controlled FREEDOM Trial and Its Extension , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  P. Tugwell,et al.  AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both , 2017, British Medical Journal.

[15]  G. Lupoli,et al.  Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole , 2017, Front. Pharmacol..

[16]  Susan Y. Smith,et al.  Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1–34) , 2017, Regulatory toxicology and pharmacology : RTP.

[17]  C. Cooper,et al.  Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG , 2017, Journal of bone oncology.

[18]  Jiwen Li,et al.  Preventive effect of zoledronic acid on aromatase inhibitor-associated bone loss for postmenopausal breast cancer patients receiving adjuvant letrozole , 2016, OncoTargets and therapy.

[19]  S. Davis,et al.  Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. , 2016, Bone.

[20]  E. Rutgers,et al.  Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials , 2015, The Lancet.

[21]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[22]  E. Perez,et al.  5‐year follow‐up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial , 2015, Cancer.

[23]  R. Greil,et al.  Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial , 2015, The Lancet.

[24]  S. Greenspan,et al.  Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial , 2015, Osteoporosis International.

[25]  Zhenyu Yan,et al.  Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis. , 2014, Archives of medical research.

[26]  H. Linden,et al.  Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. , 2014, The Lancet. Oncology.

[27]  Suchandra Sen,et al.  The Efficacy of Bisphosphonates in Preventing Aromatase Inhibitor Induced Bone Loss for Postmenopausal Women with Early Breast Cancer: A Systematic Review and Meta-Analysis , 2014, Journal of oncology.

[28]  J. Forbes,et al.  Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. , 2013 .

[29]  Y. Isogai,et al.  Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)). , 2012, The Journal of toxicological sciences.

[30]  E. Perez,et al.  Final 5‐year results of Z‐FAST trial , 2012, Cancer.

[31]  T. Ishikawa,et al.  Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results , 2012, Breast Cancer Research and Treatment.

[32]  P. Neven,et al.  Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. , 2012, Clinical breast cancer.

[33]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[34]  Seung Ah Lee,et al.  Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients , 2011, Breast Cancer Research and Treatment.

[35]  V. Stearns,et al.  Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management , 2011, Breast Cancer Research.

[36]  Jack Cuzick,et al.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. , 2010, The Lancet. Oncology.

[37]  P. Neven,et al.  Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  I. Reid,et al.  Characterization of and risk factors for the acute-phase response after zoledronic acid. , 2010, The Journal of clinical endocrinology and metabolism.

[39]  U. Dafni,et al.  Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial , 2010, Breast Cancer Research.

[40]  D. Mavroudis,et al.  Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. , 2010, Gynecologic oncology.

[41]  R E Coleman,et al.  The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer , 2010, British Journal of Cancer.

[42]  J. Mackey,et al.  Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Forbes,et al.  Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  E. Perez,et al.  Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. , 2009, Clinical breast cancer.

[45]  E. Perez,et al.  Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC , 2009, Breast Cancer Research and Treatment.

[46]  D. Dodwell,et al.  Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer , 2008, Clinical Cancer Research.

[47]  P. Neven,et al.  Effective inhibition of aromatase inhibitor‐associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole , 2008, Cancer.

[48]  M. Beckmann,et al.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[51]  E. Perez,et al.  Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. Cawthorn,et al.  Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. , 2007, The Lancet. Oncology.

[53]  E. Perez,et al.  Aromatase inhibitors and bone loss. , 2006, Oncology.

[54]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[55]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[56]  J. Manola,et al.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  D. Burr,et al.  Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[58]  P. Hadji.  Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. , 2009, Critical reviews in oncology/hematology.